The cost of capital is less than the cost of innovation…a remarkable shift in the world of M&A
http://www.ft.com/cms/s/0/6aad8ebe-e9c0-11e4-b863-00144feab7de.html#axzz3YTZwnnI3 The attached article from the FT provides a good insight into a remarkable change in the levels of activity in M&A, particularly in pharmaceuticals ($468 billion of transactions announced in 2015, an almost unprecedented rise and certainly the most significant increase since before the global financial crisis). A frenzy of activity therefore, some of which may be driven by not wishing to be left out rather than a solid […]